As of Oct 17
| -0.06 / -4.41%|
The 4 analysts offering 12-month price forecasts for Outlook Therapeutics Inc have a median target of 8.50, with a high estimate of 12.00 and a low estimate of 4.00. The median estimate represents a +553.85% increase from the last price of 1.30.
The current consensus among 4 polled investment analysts is to Buy stock in Outlook Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.